Psyence Biomed (NASDAQ: PBM) has announced that its Chief of Global Impact, Mary-Elizabeth Gifford, will be a featured speaker at Psychedelic Science 2025 (PS2025), the premier international conference dedicated to psychedelic research, biopharma, medicine, policy, and culture. Organized by the Multidisciplinary Association for Psychedelic Studies (MAPS), the event is scheduled for June 16-20, 2025, in Denver, Colorado. Gifford is set to contribute to a panel titled 'We are the Guardrails: Profit with Purpose,' focusing on the intersection of business ethics and psychedelic medicine.
As Chief of Global Impact at Psyence Biomed, Gifford plays a pivotal role in bridging the gap between psychedelic research, regulatory frameworks, and patient care. Psyence Biomed stands out as the first Nasdaq-listed biopharmaceutical company dedicated to developing nature-derived psilocybin medicines for FDA approval, aiming to meet the urgent need for innovative mental health treatments, especially in palliative care.
This participation underscores Psyence Biomed's leadership in the psychedelic biopharmaceutical sector and its commitment to ethical business practices and evidence-based treatment development. The company's focus on non-synthetic psilocybin and ibogaine-based therapies represents a significant step forward in addressing mental health disorders with natural psychedelic compounds.
For further details on Psyence Biomed's initiatives and Gifford's upcoming presentation, interested parties can view the full press release here.
